PhD in Medicine, 2012- Prognostic and predictive factors of response in patients with locally advanced bladder carcinoma treated with neoadjuvant chemotherapy.
Fellowship in Urological Tumors, 2013-2015, Hospital Universitario 12 de Octubre
Publications
Font A, Taron M, Gago JL, Costa C, Sánchez JJ, Carrato C, Mora M, Celiz P, Perez L, Rodríguez D, Gimenez-Capitan A, Quiroga V, Benlloch S, Ibarz L, Rosell R. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann Oncol. 2011 Jan;22(1):139-144. IF: 7.3
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial The Lancet Oncology 2020. 21-1, pp.33-43. IF: 41,3
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. Front Oncol 2021;11;645026. IF: 5,3
Fort-Casamartina, E., Muñoz-Sanchez, C., Rigo-Bonnin, R.F. et al. First reported double drug–drug interaction in a cancer renal patient under everolimus treatment: therapeutic drug monitoring and review of literature. Eur J Med Res 28, 202 (2023). IF: 4,2
Senior Clinical Data Manager & Study Coordinator at L’Institut Català d’OncologiaSenior Clinical Data Manager & Study Coordinator at L’Institut Català d’Oncologia